NeuroScientific Biopharmaceuticals Earnings Call Transcripts

Fiscal Year 2025

Investor Update

A new stem cell platform was acquired, shifting focus to Crohn's disease and other high-value indications. Early clinical data is strong, with a special access program underway and phase two trials planned. Manufacturing and advisory partnerships de-risk development and support future expansion.

Read full transcript →